Division of Gynecologic Oncology, Washington University School of Medicine, 4901 Forest Park Ave, 9th Floor, COH, Suite 905, St. Louis, MO, 63108, USA.
Curr Oncol Rep. 2021 Nov 4;23(12):139. doi: 10.1007/s11912-021-01129-4.
Endometrial cancer is a highly treatable cancer; however, 13 to 15% of cases recur. Traditional cytotoxic chemotherapies have produced modest results, but new treatments show promise. This information was compiled from an extensive literature search, which was completed in order to summarize current data in this review. Our objective was to describe new therapies for recurrent endometrial cancer in the last 5 years.
New targeted therapies are being identified for advanced and recurrent endometrial cancer. Within the last 5 years, pembrolizumab and lenvatinib have improved survival in advanced or recurrent endometrial cancer. Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer. Patients with recurrent endometrial cancer are often difficult to salvage. Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.
子宫内膜癌是一种高度可治疗的癌症，但仍有 13%至 15%的病例会复发。传统细胞毒性化疗的效果有限，但新的治疗方法显示出了希望。这些信息是通过广泛的文献检索收集的，旨在总结本综述中的最新数据。我们的目的是描述过去 5 年内复发性子宫内膜癌的新疗法。
新的靶向疗法正在被确定用于治疗晚期和复发性子宫内膜癌。在过去的 5 年中，pembrolizumab 和 lenvatinib 改善了晚期或复发性子宫内膜癌患者的生存。同样，曲妥珠单抗在 HER2 阳性的子宫浆液性癌中也显示出疗效。复发性子宫内膜癌患者通常难以救治。传统化疗的反应率很低。免疫疗法和其他靶向疗法在复发性疾病中均显示出了希望。
